The results in Figure 6 revealed that high expression of CD20 and PR was associated with lower overall survival probability in ESCA and STAD patients; increasing levels of protein AR, HER3, MYH11, and SMAD1 were also associated with poor overall survival in STAD patients. This evidence concerns the gene MYH11 and gastric adenocarcinoma.